Skip to content

AxoGen

US · AXGN #2714 by market cap Listed 1970
55.75 -0.60 -1.06%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.4 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
99.29% -1.35pp
Institutions
314 +6
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund71.31%
Hedge Fund17.69%
Public Company6.34%
Individual/Insider1.91%
Private Company1.71%
Government Pension Fund1.05%
Insurance Company0.73%
VC/PE Fund0.41%

Top holders as of 2026-09-30

BlackRock 7.67% · 4.58M sh
Divisadero Street Capital Management, LP 6.67% · 3.98M sh
First Light Asset Management, LLC 4.60% · 2.75M sh
FMR 4.42% · 2.64M sh
Vanguard Capital Management, LLC 4.07% · 2.43M sh
Morgan Stanley 3.00% · 1.79M sh
Artemis Investment Management LLP 2.98% · 1.78M sh
Geode Capital Management, LLC 2.76% · 1.65M sh
Polar Capital Holdings Plc 2.51% · 1.50M sh
Citadel Advisors LLC 2.32% · 1.36M sh
Wellington Management Group 2.33% · 1.39M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 29 buys · 18 sells

NameRoleStake
Erick DeVinney Chief Scientific Officer 0.40%
Amy McBride-Wendell Lead Independent Director 0.18%
Doris Quackenbush Chief Revenue Officer 0.15%
Jens Kemp Chief Marketing Officer 0.12%
Lindsey Hartley Chief Financial Officer 0.11%
Michael Dale Chief Executive Officer 0.11%
Alan Levine Independent Director 0.09%
Marc Began Executive VP, General Counsel, Secretary & Chief Compliance Officer 0.08%
Paul Thomas Independent Chairperson 0.05%
William Burke Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-01 Joseph Tyndall Independent Director Automatic Disposition -3,500 $49.70
2026-08-10 Amy McBride-Wendell Lead Independent Director Derivative Exercise and Sale -13,353 $14.85–48.42
2026-08-09 Marc Began Executive VP, General Counsel, Secretary & Chief Compliance Officer Derivative Exercise and Sale -67,500 $8.16–47.35
2026-08-06 Kathy Weiler Independent Director Automatic Disposition -14,150 $45.30
2026-06-23 Paul Thomas Independent Chairperson Other Derivative Acquisition +5,579 --
2026-06-23 Amy McBride-Wendell Lead Independent Director Other Derivative Acquisition +4,392 --
2026-06-23 John Johnson Independent Director Other Derivative Acquisition +4,392 --
2026-06-23 Kathy Weiler Independent Director Other Derivative Acquisition +4,392 --
2026-06-23 Alan Levine Independent Director Other Derivative Acquisition +4,392 --
2026-06-23 William Burke Independent Director Other Derivative Acquisition +4,392 --
2026-06-23 Joseph Tyndall Independent Director Other Derivative Acquisition +4,392 --
2026-06-18 Paul Thomas Independent Chairperson Derivative Exercise and Retained +18,867 --
2026-06-18 Amy McBride-Wendell Lead Independent Director Derivative Exercise and Retained +14,150 --
2026-06-18 John Johnson Independent Director Derivative Exercise and Retained +14,150 --
2026-06-18 Kathy Weiler Independent Director Derivative Exercise and Retained +14,150 --
2026-06-18 Alan Levine Independent Director Derivative Exercise and Retained +14,150 --
2026-06-18 William Burke Independent Director Derivative Exercise and Retained +14,150 --
2026-06-18 Joseph Tyndall Independent Director Derivative Exercise and Retained +14,150 --
2026-05-07 Amy McBride-Wendell Lead Independent Director Derivative Exercise and Sale -1,647 $14.85–42.60
2026-05-06 John Johnson Independent Director Derivative Exercise and Sale -11,050 $7.04–43.26

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

AxoGen discussion 0 comments

Add a comment